Abstract
This study assessed the real-world vaccine effectiveness (RVE) of a 2-dose schedule of BNT162b2 against the Omicron variant among Thai adolescents aged 12 to 18 in the Eastern Region. A test-negative matched 1:1 case-control design was conducted using nationwide records of RT-PCR tests and vaccination history. Cases were matched with controls by the specimen collection date and residential province. Conditional logistic regression was used to determine the RVE. From January to June 2022, when Omicron prevailed, 7,770 adolescents (3,758 detected and 4,012 undetected) were reported to the system. At the time of the RT-PCR test, 684 (14%), 295 (6%), 3,834 (78%), 104 (2%), and three adolescents had received no, one, two, three, and four doses of any COVID-19 vaccines, respectively. A total of 3,304 eligible adolescents with 2-dose of BNT162b2 with a median (interquartile range (IQR)) age of 16 (14–17) years were analyzed. The median (IQR) interval from the last vaccination to RT-PCR test was 91 (55–125) days. The age-adjusted RVE of BNT162b2 against infection was 22% (95% confidence interval (CI) 5–35%). The highest RVE was 71% (95% CI -9–92%), which occurred 15–29 days after vaccination. We therefore recommend that a booster dose be considered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Outbreak, Surveillance, Investigation & Response (OSIR) Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
